<div id="readability-page-1"><div>         <div>                                                                  <p>,  /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that the first patient has been dosed in a global Phase 2b clinical trial sponsored by Novartis evaluating DII235, also known as BW-20829, in adults with elevated Lipoprotein (a) (Lp(a)) and Atherosclerotic Cardiovascular Disease (ASCVD). In connection with the molecule's advancement into Phase 2b under its exclusive license and collaboration agreement with Novartis, Argo Biopharma will receive milestone payments that will support ongoing research and development efforts across its hepatic and extra-hepatic siRNA portfolio. BW-20829 is the sixth asset in Argo's pipeline to enter mid-stage global clinical development.</p> <p>&#34;We are pleased that Novartis has advanced BW-20829 into Phase 2b clinical development&#34; said Dr. Dongxu Shu<b>,</b> Co-Founder, Chairman of the Board, and Chief Executive Officer of Argo Biopharma. &#34;This milestone underscores the strength of Argo's discovery and early clinical development capabilities, together with Novartis' scientific rigor and speed of execution to bring forward therapeutic options for patients' unmet cardiovascular needs. Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, and the progression of BW-20829 into Phase 2b represents a meaningful step toward the potential development of additional therapeutic options for patients with elevated cardiovascular risk.&#34;</p> <p>BW-20829 is an siRNA therapeutic developed from Argo's proprietary RADS™ platform, and is designed to enable potent, durable gene silencing with differentiated safety and delivery characteristics through hepatic delivery. Argo Biopharma continues to advance a cardiovascular and specialty disease pipeline via hepatic siRNA, and maintains an earlier-stage portfolio of extra-hepatic siRNAs targeting multiple tissue types and therapeutic areas. Information regarding the Phase 2b clinical study can be found on ClinicalTrials.gov. Study Details | NCT07235046 | A Study of DII235 in Adults With Elevated Lipoprotein(a) | ClinicalTrials.gov</p> <p><b>About Argo Biopharma</b></p> <p>Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established a robust and diverse pipeline of RNAi molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases. Currently, Argo Biopharma has six RNAi candidates in clinical development.</p> <p>For more information, visit www.argobiopharma.com.</p> <p>SOURCE Argo Biopharmaceutical Co., Ltd</p> <p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI1Jk5ld3NJdGVtSWQ9Q0w2OTgxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjUxOTAwUFJfTkVXU19VU1BSX19fX19DTDY5ODEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI1Jk5ld3NJdGVtSWQ9Q0w2OTgxMyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjUxOTAwUFJfTkVXU19VU1BSX19fX19DTDY5ODEz"/></p></div>       </div></div>

LABD

SBIO

<p>Argo Biopharmaceutical Co., Ltd. announced the dosing of the first patient in a Phase 2b trial for its siRNA therapeutic BW-20829, targeting elevated Lipoprotein (a) in patients with Atherosclerotic Cardiovascular Disease. This milestone, part of a collaboration with Novartis, will provide milestone payments to support Argo's research. BW-20829 is designed for effective gene silencing and is the sixth asset in Argo's clinical pipeline. The trial details can be found on ClinicalTrials.gov.</p>

prnewswire

Invesco Biotechnology & Genome ETF

NOVARTIS AG

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares US Pharma

19:00 ET
			
			
				Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)

19:00 ET Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)